ACADEMISCH ZIEKENHUIS MAASTRICHT

Their core work

Maastricht University Medical Centre (azM) is a major Dutch academic hospital combining clinical care with translational research in cardiovascular disease, oncology, and digital health. They bring real-world clinical infrastructure — patient cohorts, imaging facilities, and surgical expertise — into EU research consortia. Their strength lies in running clinical trials and validating new treatments and digital health tools in hospital settings, bridging the gap between laboratory research and bedside application.

What they specialise in

How they've shifted over time

In the early phase (2015–2018), azM focused on interventional cardiology and surgical innovation — transcatheter procedures, aortic repair techniques, and immuno-oncology clinical trials. From 2019 onward, the emphasis shifted decisively toward digital health infrastructure, patient self-management through eHealth/mHealth platforms, and citizen-centred health data exchange. This mirrors a broader hospital-level transition from purely clinical research toward technology-enabled care models and patient empowerment.

azM is moving from traditional clinical trial participation toward digitally-enabled care delivery and health data interoperability — expect future interest in AI diagnostics, remote monitoring, and EHR-based research.

How they like to work

azM exclusively participates as a partner or third party — they have never coordinated an H2020 project, which is typical for large university hospitals that contribute clinical expertise and patient access rather than project management. With 127 unique partners across 21 countries, they operate within large, diverse consortia. This means they are experienced consortium members who can deliver on clinical work packages without needing to drive the overall project direction.

azM has collaborated with 127 unique partners across 21 countries, indicating a broad European network built through participation in medium-to-large health consortia. Their connections likely span academic hospitals, universities, and health-tech companies across Western and Southern Europe.

What sets them apart

azM offers a rare combination of deep cardiovascular surgical expertise and growing digital health capabilities within a single academic hospital. For consortium builders, they provide both the clinical trial infrastructure needed for medical device or drug validation and the digital health experience for eHealth/mHealth pilots. Their dual strength in hands-on surgical innovation and patient-facing digital tools makes them a versatile clinical partner for health projects that span physical treatment and digital care delivery.

Highlights from their portfolio

• STARS
  Largest EC contribution (EUR 3.08M) — a flagship project on patient empowerment through eHealth/mHealth self-management across the full care continuum.
• PAPA-ARTIS
  A long-running randomised controlled trial (2017–2024) tackling a critical surgical problem: preventing paraplegia during complex aortic aneurysm repair.
• ICU4Covid
  Rapid-response project deploying AI-driven telemedicine and robotics for ICU management during Covid-19, showing azM's capacity to contribute to crisis-driven innovation.